Abstract:OBJECTIVE:To investigate the prokaryotic expression of proteins pneumococcal endopeptidase O (PepO) and pneumococcal surface adhesin A (PsaA) in Streptococcus pneumoniae and their immunoprotective effect as vaccine candidate proteins.METHODS:Specific primers of target gene fragments were designed, and then PCR amplification was performed to establish recombinant plasmids pET28a(+)-pepO and pET28a(+)-psaA, which were transformed into host cells, Escherichia coli BL21 and DE3, respectively, to induce expression. Highly purified target proteins PepO and PsaA were obtained after purification. Mucosal immunization was performed for BALB/c mice and specific antiserum was prepared. ELISA was used to measure the antibody titer, and Western blot was used to analyze the specificity of the antiserum of target proteins. The mice were randomly divided into negative control group, PepO group, PsaA group, and PepO+PsaA combined immunization group, with 18 mice in each group. The models of different serotypes of Streptococcus pneumoniae infection were established to evaluate the immunoprotective effect of target proteins used alone or in combination.RESULTS:The target proteins PepO and PsaA were successfully obtained and Western blot demonstrated that the antiserum of these proteins had good specificity. There was no significant difference in the titers of IgA in saliva and IgG in serum between the PepO group and the combined immunization group (P>0.05); however, these two groups had significantly higher antibody titers than the PsaA group (P<0.05). The PepO, PsaA, and combined immunization groups had significantly higher protection rates for mice infected with Streptococcus pneumoniae D39 and CMCC31436 in the nasal cavity than the negative control group (P<0.05). The PepO and combined immunization groups had a significantly higher protection rate for mice infected with Streptococcus pneumoniae D39 than the PsaA group (P<0.05). The results of colonization experiment showed that compared with the control group, the PepO, PsaA, and combined immunization groups showed a significant reduction in the colonization of Streptococcus pneumoniae (CMCC31693 and CMCC31207) in the nasopharynx and lung (P<0.05). The combined immunization group showed a better effect on reducing the colonization of CMCC31207 in the lung than the PepO and PsaA alone groups.CONCLUSIONS:Combined PepO/PsaA vaccines may produce a better protective effect by mucosal immunization compared with the vaccine used alone in mice. The combined vaccines can effectively reduce the colonization of Streptococcus pneumoniae in the nasopharynx and lung. Therefore, such protein vaccines may have a great potential for research and development.

Preparation of Pnemnococcal Conjugate Vaccine and Its Inmnmogenicity in Infant Mice

The experimental research of tne preparation for pneumococcal conjugate vaccine using pneumolysin as a protein carrier and its immumogenicity in mice

Evaluation of the immunogenicity and efficacy of a Hib polysaccharide-protein conjugate vaccine by using PsaA as carrier protein

Preparation of Meningococcal Group A Conjugate Vaccine

Studies on Vaccine Control and Immunogenicity of Polysaccharides of Streptococcus pneumoniae

[Study on the Bactericidal Antibody Against Neisseria Meningitidis Serogroup C Strains after Immunization with a Divalent Polysaccharide (A Plus C) Vaccine].

Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.

Preparation and immunogenicity of capsular polysaccharide–surface adhesin A (PsaA) conjugate of Streptococcus pneumoniae

Optimization of the Process for Preparing Bivalent Polysaccharide Conjugates to Develop Multivalent Conjugate Vaccines against Streptococcus pneumoniae or Neisseria meningitidis and Comparison with the Corresponding Licensed Vaccines in Animal Models

Protection Elicited by Nasal Immunization with Pneumococcal Surface Protein A (pspa) Adjuvanted with Bacterium-Like Particles Against Streptococcus Pneumoniae Infection in Mice

Comparative evaluation of a newly developed 13-valent pneumococcal conjugate vaccine in a mouse model

Comparison Of Immunogenicity And Protection Of Two Pneumococcal Protein Vaccines Based On Psaa And Pspa

Preparation of New Protein Carrier of Vaccine Against Pneumococcal Otitis Media with Genetic Engineering Technology

Novel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for S. pneumoniae

Robust Immune Response and Protection against Lethal Pneumococcal Challenge with a Recombinant BCG-PspA-PdT Prime/Boost Scheme Administered to Neonatal Mice

Effect of individual conjugate dose on immunogenicity of type 6B pneumococcal polysaccharide-N. meningitidis outer membrane protein complex conjugate vaccines in infant rhesus monkeys

Immunization With A Zmpb-Based Protein Vaccine Could Protect Against Pneumococcal Diseases In Mice

Studies on Preparation and Immunogenicity of Streptococcus Pneumoniae Type 2 Polysaccharide-Tetanus Toxoid Conjugate Vaccine

[Immunoprotective Effect of Combined Pneumococcal Endopeptidase O and Pneumococcal Surface Adhesin A Vaccines Against Streptococcus Pneumoniae Infection].

Preliminary study on the application of PspA as carrier

Development of a conjugate vaccine against invasive pneumococcal disease based on capsular polysaccharides coupled with PspA/family 1 protein of Streptococcus pneumoniae.